Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...
Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results